Straits Times Index
3,219.00 -1.98 (-0.06%) S&P 500
3,948.72 +11.75 (+0.30%) Dow
32,105.25 +75.14 (+0.23%) Nasdaq
11,787.40 +117.44 (+1.01%) Bitcoin USD
28,189.39 +976.89 (+3.59%) CMC Crypto 200
616.80 +19.34 (+3.24%)
VRTX Jun 2023 320.000 call
| Previous close | 9.60 |
| Open | 10.21 |
| Bid | 10.70 |
| Ask | 11.60 |
| Strike | 320.00 |
| Expiry date | 2023-06-16 |
| Day's range | 10.21 - 10.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 201 |
- Zacks
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
This Cathie Wood Stock Could Nearly Double, According to Wall Street
One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.
- Motley Fool
This Is My Highest-Conviction Stock to Own in 2023 and Beyond
While one could say the same about many biotech companies, Vertex has an advantage very few of its peers do: For CF patients, it's the only game in town. Vertex markets the only medicines that target the underlying causes of CF. In 2022, the company's revenue of $8.93 billion jumped by 18% year over year.
